Modality
Peptide
MOA
MDM2i
Target
EZH2
Pathway
PI3K/AKT
RBWilmsMM
Development Pipeline
Preclinical
~Feb 2022
→ ~May 2023
Phase 1
Aug 2023
Phase 1Current
NCT08481446
1,314 pts·Wilms
2023-08→TBD·Recruiting
1,314 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-273mo agoOrphan Drug· Wilms
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q4
P1
Recruit…
Catalysts
Orphan Drug
2025-12-27 · 3mo ago
Wilms
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08481446 | Phase 1 | Wilms | Recruiting | 1314 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |